Insights & news

France Presents Plan To Tackle Medicine Shortages and Adds Sense of Urgency to European Discussions

  • 09/07/2019
  • Articles

Agnès Buzyn, the French Minister for Solidarity and Health, presented on 8 July 2019 a four-year plan to tackle medicine shortages in France (see, annex). The plan is the latest move in what is gradually becoming a wave of new rules and policy initiatives across Europe to fight the lack of availability of specific medicines. The plan reflects a four-pronged approach that includes the following measures:



  1. Increased transparency and enhanced channels of communication between all stakeholders, including individual patients and patient organisations 
  1. New strategies for preventing, mitigating and managing medicine shortages 
  • Power for community pharmacists, subject to conditions, to substitute out-of-stock medicines of major therapeutical importance (“médicaments d’intérêt thérapeutique majeur “ – “MITM”);
  • Focus on antibiotics that run an out-of-stock risk;
  • Further development of management plans for out-of-stock medicines (“plans de gestion des pénuries” – “PGP”) and creation of enhanced management plans for medicines that have already faced supply problems (“PGP renforcé”);
  • Specific measures targeting hospitals and wholesaler-distributors.
  1. Reinforced national coordination and increased European cooperation 
  • Increased powers for regulator (“Agence nationale de sécurité du médicament et des produits de santé – “ANSM”) to tackle supply quota systems (“contingentements”) and to import substitute medicines, including competing products;
  • Powers for specific public institutions to stock and distribute MITMs;
  • Pursuit of European rules, including definitions of key concepts such as medicine shortage and medicines of major therapeutical importance;
  • Advocacy in Europe of European or French production of key pharmaceutical ingredients and medicines;
  • Increased focus on joint procurement of essential vaccines;
  • Exchange of information between Member States on medicines hit by shortages.
  1. Modified institutional architecture 
  • The new plan will be implemented and steered by a “Comité de pilotage” (“COPIL”) and supported by a task force composed of representatives of the various competent ministries. ANSM will also be given a more prominent role.     

The French plan is certain to be met with close attention in France and abroad as it plays into the often expressed and at times overstated fears of supply disruption of medicines. Following repeated similar statements by other policy makers and interested parties (see e.g., Van Bael & Bellis Life Sciences Newsflash of 28 June 2019), the plan is certain to catapult this issue on the list of top health priorities of the incoming European Commission.


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 11/09/2019
    • Articles

    Stella Kyriakides Commissioner-Designate for Health

    Stella Kyriakides, a member of the Cypriot parliament, a trained psychologist and a forceful advocate of patient rights (she is a past President of Europa Donna, the breast cancer patient group), has been entrusted with the health portfolio by Ursula von der Leyen, the President-elect of the incoming European Commission. Like the other designated Commissioners, Ms. Kyriakides’ appointment still has to be approved by the European Parliament, but with her colleagues she is expected to take up her position in November 2019.

    Read more
    • 09/09/2019
    • Articles

    Belgium - Minister of Economic Affairs Uses Price Regulation Powers against Leadiant's CDCA

    Minister of Economic Affairs Wouter Beke took action against pharmaceutical firm Leadiant and, making use of his price regulation powers, reduced the price of chenodeoxycholic acid Leadiant (“CDCA”), a medicine indicated for the treatment of patients afflicted with cerebrotendinous xanthomatosis, a rare metabolic disorder (“CTX”). CDCA was designated as an orphan medicine in December 2014, but its active substance is no longer patented and has been used for many years as an inexpensive treatment for cholesterol gallstones. In a press release (see attached, only the Dutch version is available), the Minister says that he lowered the price of what would seem to be a presentation of 100 tablets of 250mg of CDCA Leadiant to EUR 3,653.25 ex factory, while Leadiant had sought a price of EUR 14,000 ex factory. The presentation at issue covers the treatment of CTX during approximately one month. The Minister has also urged the Belgian Competition Authority (“BCA”) to review as a matter of priority the alleged abuse of a dominant position of which Leadiant might be guilty. The case before the BCA results from a complaint filed by consumer organisation Test-Aankoop/Test-Achats earlier this year (see, Van Bael & Bellis Life Sciences Newsflashes of 9 April 2019 and 11 February 2019). Additionally, the Minister called on the European Commission to review the rules governing orphan medicines. However, that call is superfluous as an assessment of these rules has already been under way for quite some time (see, Van Bael & Bellis Life Sciences Newsflash of 18 October 2018) and the outcome of this exercise is expected to be high on the agenda of the incoming European Commission.

    Read more
    • 05/09/2019
    • News

    Medicines Cooperation - Sweden to Join International Horizon Scanning Initiative

    On 4 September 2019, the Dutch Minister for Medical Care, Bruno Bruins, announced plans for Sweden to join the impending International Horizon Scanning Initiative (“IHSI”) (see, attached press release). IHSI, which is expected to start in October 2019, is a form of international cooperation that seeks to identify innovative medicines before they reach the market. It will inform decision-making on treatment and budgets in the participating countries. IHSI is just one example of a broader trend of expanding international cooperation on medicines in a range of areas and in varying geographical constellations. Last month, Minister Bruins had already announced that Canada would also become a member of IHSI (see, Van Bael & Bellis Life Sciences Newsflash of 18 July 2019). When airing the intentions of Sweden, Minister Bruins expressed the hope that IHSI would be able to begin operations with 10 member countries. Other known aspiring members include Belgium, Ireland, Luxemburg and The Netherlands.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *